Welcome to our dedicated page for Springworks Therapeutics news (Ticker: SWTX), a resource for investors and traders seeking the latest updates and insights on Springworks Therapeutics stock.
SpringWorks Therapeutics, Inc. (SWTX) is a clinical-stage biopharmaceutical company pioneering targeted therapies for rare diseases and oncology. This news hub provides investors and healthcare professionals with essential updates on therapeutic advancements, regulatory milestones, and strategic collaborations.
Access authoritative information on SWTX's precision medicine pipeline, including FDA communications, clinical trial developments, and partnership announcements. Our curated collection features:
• Regulatory updates on approved therapies and review timelines
• Clinical trial progress across rare disease and oncology programs
• Research collaborations with academic institutions and industry leaders
• Scientific presentations at major medical symposiums
Bookmark this page for real-time access to verified SWTX developments. For comprehensive analysis of the company's therapeutic pipeline and market position, visit regularly for the latest updates directly from primary sources.
SpringWorks Therapeutics (Nasdaq: SWTX) has announced the appointment of Carlos Albán to its Board of Directors. Albán, the former Vice Chairman and Chief Commercial Officer at AbbVie, brings over 30 years of experience in global commercial strategy. His leadership is expected to be crucial as SpringWorks transitions to a commercial-stage company. Under Albán's tenure at AbbVie, sales surged from $18 billion in 2013 to over $45 billion in 2020. SpringWorks focuses on developing treatments for severe rare diseases and cancer.
SpringWorks Therapeutics (Nasdaq: SWTX) announced a virtual R&D Day on June 10, 2022, showcasing advancements in their oncology pipeline. Key highlights include the upcoming NDA filing for Nirogacestat in Desmoid Tumors expected in late 2022 and a new Phase 2 study for ovarian granulosa cell tumors. Ongoing collaborations with BCMA therapies and significant focus on Mirdametinib for rare tumors were also discussed. The company aims to provide approved therapies for desmoid tumors by 2023 and anticipates two approvals by 2025.
SpringWorks Therapeutics (Nasdaq: SWTX) will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 8:40 a.m. PT / 11:40 a.m. ET. The event will be accessible via a live webcast on the company’s Investors & Media page. SpringWorks is focused on developing targeted therapies for severe rare diseases and cancer, with 18 programs in development, including two in late-stage trials. The company aims to enhance patient outcomes through strategic partnerships and innovative clinical approaches.
SpringWorks Therapeutics (SWTX) announced initial clinical data from a Phase 1/2 study of nirogacestat in combination with BLENREP for relapsed or refractory multiple myeloma. Data revealed a promising safety profile, with significant reductions in ocular adverse events compared to single-agent treatment. Additionally, long-term follow-up from a NCI-sponsored Phase 2 study of nirogacestat in desmoid tumors showed no disease progression and median treatment duration of 4.4 years. This data will be presented at the ASCO Annual Meeting, June 3-7, 2022, in Chicago.
SpringWorks Therapeutics (SWTX) announced positive topline results from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor for desmoid tumors. The trial achieved its primary endpoint, showing a 71% reduction in disease progression risk compared to placebo (Hazard Ratio: 0.29; P < 0.001). All key secondary endpoints, including objective response rate and patient-reported outcomes, also showed statistically significant improvement. Nirogacestat was generally well tolerated. The company plans to submit a NDA to the FDA in the second half of 2022.
SpringWorks Therapeutics (Nasdaq: SWTX) will host a virtual R&D Day for investors on June 10, 2022, at 10:00 am ET. The event will feature presentations from the executive leadership team and external experts in the company's development areas, followed by a Q&A session. Interested participants can register here. The webcast will be available on the SpringWorks website after the event.
SpringWorks Therapeutics reported its Q1 2022 financial results, highlighting a net loss of $61.8 million, or $1.26 per share, compared to a loss of $29.8 million, or $0.62 per share, in Q1 2021. R&D expenses surged to $34.1 million, up from $17.4 million, mainly due to increased personnel costs and trial expenses. The company continues to advance its oncology pipeline, with 18 development programs. Key upcoming events include topline data from the Phase 3 DeFi trial expected in Q2 2022 and initial data at the ASCO Annual Meeting.
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) has announced a clinical trial collaboration with Regeneron Pharmaceuticals, Inc. to evaluate nirogacestat in combination with Regeneron's REGN5458 for treating relapsed multiple myeloma. This partnership marks SpringWorks' eighth collaboration focused on BCMA therapies. Nirogacestat, currently in Phase 3 trials for desmoid tumors, aims to enhance the efficacy of BCMA-targeted therapies by preserving membrane-bound BCMA. Regeneron will lead the clinical study while SpringWorks will provide nirogacestat. The drug has received multiple FDA designations for its potential benefits.
SpringWorks Therapeutics (SWTX) reported no revenue for Q4 and full-year 2021, a decline from $35 million in the previous year. R&D expenses surged to $29.3 million for Q4 and $101.7 million for the year, driven by increased personnel and trial costs. General and Administrative expenses also rose to $26.5 million in Q4, resulting in a net loss of $56.1 million for Q4 and $173.9 million for the year. Despite these losses, cash reserves stood strong at $432.7 million as of December 31, 2021. Upcoming milestones include topline data from the Phase 3 DeFi Trial anticipated in H1 2022.
SpringWorks Therapeutics, focused on rare diseases and cancer treatments, announced its participation in three upcoming investor conferences. The events include the Guggenheim Oncology Conference on February 10, Cowen 42nd Annual Health Care Conference on March 7, and Barclays Global Healthcare Conference on March 16. Webcasts will be available on the company’s website for each conference, with replays offered for a limited time. SpringWorks is advancing 17 development programs and emphasizes a precision medicine approach.
